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Abstract
Background: HER2 targeted therapies including trastuzumab and more recently lapatinib have significantly
improved the prognosis for HER2 positive breast cancer patients. However, resistance to these agents is a
significant clinical problem. Although several mechanisms have been proposed for resistance to trastuzumab, the
mechanisms of lapatinib resistance remain largely unknown. In this study we generated new models of acquired
resistance to HER2 targeted therapy and investigated mechanisms of resistance using phospho-proteomic profiling.
Results: Long-term continuous exposure of SKBR3 cells to low dose lapatinib established a cell line, SKBR3-L,
which is resistant to both lapatinib and trastuzumab. Phospho-proteomic profiling and immunoblotting revealed
significant alterations in phospho-proteins involved in key signaling pathways and molecular events. In particular,
phosphorylation of eukaryotic elongation factor 2 (eEF2), which inactivates eEF2, was significantly decreased in
SKBR3-L cells compared to the parental SKBR3 cells. SKBR3-L cells exhibited significantly increased activity of protein
phosphatase 2A (PP2A), a phosphatase that dephosphorylates eEF2. SKBR3-L cells showed increased sensitivity to
PP2A inhibition, with okadaic acid, compared to SKBR3 cells. PP2A inhibition significantly enhanced response to
lapatinib in both the SKBR3 and SKBR3-L cells. Furthermore, treatment of SKBR3 parental cells with the PP2A
activator, FTY720, decreased sensitivity to lapatinib. The alteration in eEF2 phosphorylation, PP2A activity and
sensitivity to okadaic acid were also observed in a second HER2 positive cell line model of acquired lapatinib
resistance, HCC1954-L.
Conclusions: Our data suggests that decreased eEF2 phosphorylation, mediated by increased PP2A activity,
contributes to resistance to HER2 inhibition and may provide novel targets for therapeutic intervention in HER2
positive breast cancer which is resistant to HER2 targeted therapies.
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Introduction
Overexpression of HER2 occurs in approximately 20-25%
of breast cancers resulting in an aggressive tumor pheno-
type associated with a poor clinical outcome [1]. Following
receptor dimerization, activation of HER2 occurs through
phosphorylation of tyrosine residues in the kinase domain
resulting in the activation of downstream signaling cas-
cades, including P13K/AKT/mTOR and MAPK pathways
[2]. Anti-HER2 targeted therapies have been successfully
developed, including trastuzumab, a humanized monoclo-
nal antibody targeting the extracellular domain of HER2
[3] and lapatinib, a tyrosine kinase inhibitor that targets
the intracellular domain of HER2 and EGFR [4]. Trastuzu-
mab revolutionized the treatment of HER2 positive breast
cancer, leading to greater overall response rates and sur-
vival compared to chemotherapy alone [5]. Trastuzumab
has had the most significant clinical benefit effect in the
adjuvant treatment setting, reducing recurrence by ap-
proximately 50%. In the metastatic setting, a small but sig-
nificant proportion (9.5%) of patients achieve a durable
complete response following trastuzumab-based therapy
[6]. However, many patients do not respond, or respond
initially but develop progressive disease within 1-2 years
due to the development of resistance. Several potential
mechanisms of resistance to trastuzumab have been pro-
posed, including, but not limited to: i) loss of PTEN and/or
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mutation in P13K/AKT [7,8]; ii) expression of truncated or
cleaved HER2 (p95-HER2) [9]; iii) ligand-dependent activa-
tion of HER3 [10]; iv) crosstalk with IGF-1R [11,12]; and v)
failure to inhibit EGFR signaling [13].
Lapatinib inhibits the growth of trastuzumab-refractory
tumors, leading to its approval as a treatment for HER2
positive trastuzumab-refractory metastatic breast cancer, in
combination with capecitabine [14]. Addition of lapatinib
to capecitabine improved the median overall survival time
from 64.7 to 75.0 weeks. However, the majority of patients
developed progressive disease and ultimately died from
their disease. A synergistic interaction between trastuzumab
and lapatinib has been reported in vitro [15,16] and the
NeoALTTO study reported a significant increase in
pathological complete response for patients receiving
chemotherapy combined with both trastuzumab and
lapatinib (51.3%) compared to chemotherapy with either
trastuzumab (29.5%) or lapatinib (24.7%) alone [17].
Several proposed mechanisms of acquired lapatinib re-
sistance have been reported, including increased expression
and/or activation of: i) AXL, a MET-related membrane
bound receptor tyrosine kinase [18]; ii) myeloid cell factor-
1 (MCL-1) [19]; iii) X inhibitor of apoptosis protein (XIAP)
[20]; iv) SRC-family kinases [21]; v) RelA, leading to dis-
regulation of NFκβ signaling [22]; and vi) ER signaling
[23]. A recent study also reports constitutive activation
of mTORC1 as a mechanism of acquired lapatinib re-
sistance, with resistant cells exhibiting enhanced sensi-
tivity to mTOR inhibition [24].
In this study we describe the development and
characterization of cell line models of acquired lapati-
nib resistance. We report significant alterations in the
phospho-proteome of lapatinib resistant cells and identify
increased PP2A activity as a novel mechanism of resist-
ance to HER2 targeted therapy.
Results
Development and characterization of a cell line model of
acquired lapatinib resistance
We utilized a continuous long-term lapatinib treatment
strategy in the HER2-positive breast cancer cell line
SKBR3, to develop a cell line model of acquired resistance.
The cells were treated twice weekly with 250 nM lapatinib,
while parental control cells (SKBR3-par) were cultured
alongside the treated cells (Figure 1A). After a period of 6
months continuous treatment, the sensitivity of the
treated and un-treated cells was determined. SKBR3-par
cells showed similar sensitivity to lapatinib as the SKBR3
cells prior to the 6 month growth period (IC50 = 0.1 ± 0.01
μM). In contrast, lapatinib-conditioned cells (SKBR3-L)
exhibited a lapatinib IC50 of 6.5 ± 0.4 μM, confirming
resistance (Figure 1B). SKBR3-L cells were tested for
cross-resistance to other HER2 and EGFR targeted
agents, trastuzumab and gefitinib. SKBR3-L cells were
significantly less sensitive to trastuzumab treatment
(p = 0.003) (Figure 1C), and to gefitinib treatment (p = 0.02)
(Figure 1D), compared to SKBR3-par cells, suggesting that
SKBR3-L cells are resistant to both HER2 and EGFR inhib-
ition. We then examined the expression and phosphoryl-
ation of several key members of the HER2 and EGFR
signaling pathways in both cell lines. While the expression
of HER2, AKTand ERK was unaltered between the two cell
lines, SKBR3-L cells exhibited increased expression of
EGFR compared to SKBR3-par cells (p = 0.004) (Figure 1E).
Significant alterations in each of these proteins were
identified when we examined their phosphorylation sta-
tus. SKBR3-L cells exhibited increased levels of p-HER2
(p = 0.02) and p-EGFR (p = 0.02), and significantly de-
creased levels of p-ERK (p = 0.01) and p-AKT (p = 0.001).
Interestingly, when SKBR3-L cells were treated with lapa-
tinib the levels of p-HER2 and p-EGFR decreased, in a
similar manner to SKBR3-par cells (Figure 1E). SKBR3-L
cells did not exhibit significant alterations in the expres-
sion of XIAP, or SRC phosphorylation. They also did not
express ER nor exhibit loss of PTEN compared to SKBR3-
par cells (Additional file 1: Figure S1).
Phosphoproteomic analysis of SKBR3-par and SKBR3-L cells
The phospho-proteome of SKBR3-par and SKBR3-L cells
was compared using a combination of phospho-protein
enrichment, 2D-DIGE and mass spectrometry (MS). 2,500
spots were detected and analyzed using DeCyder differen-
tial in-gel analysis to produce 3-D images of protein
abundance and graphs of relative protein abundance
(Figure 2A). Of 2,500 spots detected on the DIGE gels, 81
spots exhibited altered abundance between SKBR3-par
and SKBR3-L cells and were picked for identification by
MS. When a p-value of ≤ 0.05 and a cut-off of 1.2-fold
change were applied, 20 phospho-proteins were signifi-
cantly higher and 21 were significantly lower in SKBR3-L
compared to SKBR3-par cells (Additional file 2: Table S1).
The proteins identified were associated with cell growth/
differentiation, metabolic processes, transcription, transla-
tion, protein folding, immune cell processes and response
to stress (Additional file 2: Table S1).
Validation of decreased eEF2 phosphorylation in
SKBR3-L cells
A number of phosphorylated forms of the protein
eukaryotic translation elongation factor 2 (eEF2) were
significantly differentially regulated in SKBR3-L compared
to parental SKBR3 cells; one form was up-regulated, while
six forms were down regulated (Additional file 2: Table S1,
Figure 2A). eEF2 plays a key role in protein synthesis and
lies downstream of the mTOR signaling pathway. The ac-
tivity of eEF2 is inhibited by its phosphorylation at Thr56
by eukaryotic elongation factor 2 kinase (eEF2k). eEF2k
activity is inhibited after phosphorylation at Ser366 by
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p70S6k, which is in turn phosphorylated and activated by
mTOR (Figure 2B). Immunoblotting with a p-eEF2thr56
specific antibody confirmed decreased levels of p-eEF2
in SKBR3-L cells compared to SKBR3-par (p = 0.001),
while no change in the levels of total eEF2 was observed
(Figure 2C). Lapatinib treatment resulted in a significant
increase in p-eEF2 in SKBR3-par cells (p = 0.001), but
not in SKBR3-L cells, suggesting that an alteration in
the signaling pathway upstream of eEF2 may prevent
lapatinib-induced phosphorylation of eEF2 and may con-
tribute to lapatinib resistance in SKBR3-L cells.
mTOR signaling does not mediate decreased
phosphorylation of eEF2
To determine if decreased p-eEF2 levels in SKBR3-L cells
are mediated by an alteration in mTOR signaling, we ex-
amined the levels of p-mTORser2448 and total mTOR.
While the total levels of mTOR were unchanged between
the two cell lines, SKBR3-L cells had significantly lower
levels of p-mTOR compared to SKBR3-par cells (p = 0.01)
(Figure 3A). However, lapatinib treatment significantly
decreased the levels of p-mTOR in both SKBR3-par
(p = 0.005) and SKBR3-L (p = 0.03) cells. Together, these
Figure 1 Development and characterization of a cell-line model of acquired lapatinib resistance. (A) Schematic depiction of the
continuous long-term lapatinib treatment strategy utilized to develop SKBR3-L cells. (B) Effect of lapatinib treatment on SKBR3-par and SKBR3-L
cells. (C) Effect of trastuzumab treatment on SKBR3-par and SKBR3-L cells. **denotes p < 0.01. (D) Effect of gefitinib treatment on SKBR3-par and
SKBR3-L cells. (E) Immunoblot analysis of total and phosphorylated HER2(Tyr1221/1222), EGFR(Tyr1173), AKT(Ser473) and ERK(Thr202/Tyr204) in cells following
24 hr lapatinib treatment. Error bars represent the mean ± SD (n = 3).
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results suggest that the downregulation of p-eEF2 ob-
served in SKBR3-L cells is not due to increased or consti-
tutive activation of mTOR. In fact, SKBR3-L cells were
significantly less sensitive to the mTOR inhibitor, rapa-
mycin, than SKBR3-par cells (p = 0.01) (Figure 3B), sug-
gesting that SKBR3-L cells have reduced dependence on
mTOR signaling for growth. Furthermore, SKBR3-par
cells treated with rapamycin alone or in combination
with lapatinib exhibited a significant increase in p-eEF2
following treatment (Figure 3C). However, treatment of
SKBR3-L cells under the same conditions had no effect
on p-eEF2. Taken together, these results suggest that the
decreased phosphorylation of eEF2 is mediated via a
non-mTOR dependent mechanism in SKBR3-L cells.
eEF2k does not mediate decreased peEF2 in SKBR3-L cells
eEF2 is the sole known substrate of eEF2k, and phosphor-
ylation of eEF2k results in its inactivation, rendering it in-
capable of phosphorylating eEF2 (Figure 2B). Therefore,
we hypothesized that increased p-eEF2k in SKBR3-L cells
may account for the decreased levels of p-eEF2 in those
cells. eEF2k is phosphorylated in an mTOR-dependent
manner at Ser366. Immunoblotting revealed significantly
higher levels of both p-eEF2kser366 and total eEF2k in
SKBR3-L cells compared to SKBR3-par cells (p-eEF2k,
p = 0.04; eEF2k, p = 0.01) (Figure 3D). However, lapati-
nib treatment of SKBR3-par cells, which increased
p-eEF2 levels, also increased p-eEF2kser366 levels (p =
0.03), suggesting that the increase in p-eEF2 levels is not
mediated by decreased mTOR-dependent phosphoryl-
ation of eEF2k. eEF2k activity can also be inhibited in an
mTOR-independent manner through phosphorylation at
Ser359 by cyclin dependent kinase 1 (CDK1) or mitogen-
activated protein kinase 13 (MAPK13). SKBR3-L cells
have significantly higher levels of p-eEF2kser359 compared
to SKBR3-par cells (p = 0.03), and SKBR3-par cells
exhibited decreased p-eEF2kser359 following lapatinib
treatment (p = 0.04). However, SKBR3-L cells also ex-
hibited a similar decrease in p-eEF2kser359 following
lapatinib treatment (p = 0.06), despite exhibiting no
alteration in p-eEF2 in response to lapatinib, thus sug-
gesting that the decreased levels of p-eEF2 in SKBR3-L
cells is not mediated by altered expression and/or phos-
phorylation of eEF2k.
Figure 2 Phospho-proteomic analysis reveals decreased levels of p-eEF2 in SKBR3-L cells. (A) Example of a 3D view of p-eEF2 protein
abundance with graphs of protein abundance analyzed by DeCyder software in SKBR3-par and SKBR3-L cells. The solid line represents the average
of three replicate measurements (dotted lines) of protein abundance. (B) Schematic depiction of mTOR-mediated activation of eEF2; active mTOR
phosphorylates and activates p70S6k, which in turn phosphorylates and deactivates eEF2k thus preventing the phosphorylation of eEF2 resulting
in active eEF2. (C) Immunoblot analysis of total and phosphorylated eEF2(Thr56) in SKBR3-par and SKBR3-L cells following 24 hr lapatinib treatment.
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We also examined inhibition of eEF2k activity in
SKBR3-par cells to determine if decreased eEF2k activity
would cause decreased p-eEF2 levels and reduced sensi-
tivity to lapatinib. Treatment of SKBR3-par cells with
the eEF2k inhibitor NH125 resulted in a significant
decrease in p-eEF2 (p = 0.01) (Figure 3E). Treatment of
SKBR3-par cells with NH125 in combination with lapati-
nib did not result in a significant decrease in lapatinib
sensitivity compared to lapatinib alone (Additional file 3:
Figure S2). This suggests that inhibition of eEF2k activity
alone is not sufficient to cause the level of lapatinib
resistance observed in SKBR3-L cells.
Dephosphorylation of eEF2 by PP2A
Protein phosphatase 2A (PP2A) activity results in the
direct dephosphorylation of multiple proteins including
eEF2 and AKT. Therefore we hypothesized that increased
PP2A activity in SKBR3-L cells may account for the de-
creased levels of p-eEF2 and p-AKT observed. PP2A
activity was measured in extracts from SKBR3-par and
SKBR3-L cells using a phosphatase assay under conditions
selective for PP2A activity. SKBR3-L cells displayed 1.8-
fold higher PP2A activity compared to SKBR3-par cells
(p = 0.02) (Figure 4A). Okadaic acid (OA), a potent lab-
grade PP2A inhibitor was used to confirm PP2A activity,
and caused a decrease in PP2A activity in both cells lines.
Treatment of SKBR3-L cells with OA resulted in a signifi-
cant increase in the levels of p-eEF2 (p = 0.02) and this ef-
fect was sustained when OA was combined with lapatinib
(p = 0.03) (Figure 4B). Levels of p-AKT were also in-
creased following OA treatment, although to a lesser ex-
tent. SKBR3-L cells were significantly more sensitive to
OA (5 nM) treatment than SKBR3-par cells in prolife-
ration assays (69.9 ± 3.7% versus 26.8 ± 9.1% growth in-
hibition, p = 0.007) (Figure 4C). Combined treatment of
SKBR3-par cells with lapatinib and OA resulted in signifi-
cantly greater inhibition of growth compared to either
lapatinib (p = 0.007) or OA alone (p = 0.012) (Figure 4D).
Importantly, significantly enhanced growth inhibition was
also observed in SKBR3-L cells following combined
treatment compared to single agent lapatinib (p = 0.005)
or OA (p = 0.012) (Figure 4E). In contrast, treatment of
SKBR3-L cells with trastuzumab and okadaic acid did
not result in enhanced growth inhibition compared to
okadaic acid alone (Additional file 4: Figure S3A). To
determine if okadaic acid combined with lapatinib was
Figure 3 mTOR and eEF2k mediated regulation of eEF2 phosphorylation. (A) Immunoblot analysis of total and phosphorylated
mTOR(Ser2448) in SKBR3-par and SKBR3-L cells following 24 hr. lapatinib treatment. (B) Effect of rapamycin on growth of SKBR3-par and SKBR3-L
cells. Error bars represent the mean ± SD (n = 3). (C) Immunoblot analysis of total and phosphorylated eEF2(Thr56) following 24 hr. treatment with
lapatinib and/or rapamycin. (D) Immunoblot analysis of total and phosphorylated eEF2k(Ser366, 359) in SKBR3-par and SKBR3-L cells following 24 hr.
lapatinib treatment. (E) Immunoblot examining the effect of NH125 alone and in combination with lapatinib on the phosphorylation of
eEF2(Thr56) in SKBR3-par cells. *denotes p≤ 0.05.
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cytostatic or cytocidal, cell cycle assays were performed.
Lapatinib alone (500 nM) induced G1 arrest (51.8 ±
1.6% compared to 41.8 ± 2.9% for untreated cells), OA
alone induced a small increase in the sub-G1 population
(12.8 ± 6.3% versus 8.9 ± 3.4% for untreated cells) and
the combination induced an increase in the sub-G1 frac-
tion (23.1 ± 8.5%) compared to either lapatinib (9.1 ± 6.7%,
p = 0.044) or OA (12.8 ± 6.3%, p = 0.083) alone (Additional
file 4: Figure S3B).
To determine if PP2A activation plays a causative role in
the development of acquired lapatinib resistance, SKBR3
cells were treated with the PP2A activator, FTY720. Fol-
lowing a 24 hour treatment with FTY720 (2.5 μM), lapati-
nib sensitivity was decreased in the SKBR3 parental cells,
with a 5.3-fold increase in the lapatinib IC50 (133.5 ± 2.3
nM compared to 25.9 ± 3.0 nM) (Additional file 5:
Figure S4). FTY720 alone, at 2.5 μM, did not signifi-
cantly affect the growth of the SKBR3 parental cells
(2.5 ± 0.2% growth inhibition).
PP2A dephosphorylation of eEF2 in HCC1954-L cells
To validate the potential of altered PP2A activity as a
mechanism of acquired lapatinib resistance, we developed
a second cell line model of acquired lapatinib resistance
(HCC1954-L) using a similar long-term lapatinib treat-
ment strategy. Continuous treatment of HCC1954 cells
resulted in the development of HCC1954-par cells and
HCC1954-L cells with lapatinib IC50 values of 0.42 ±
0.02 μM and 2.67 ± 0.08 μM, respectively (Figure 5A).
HCC1954-L cells have significantly lower levels of p-
eEF2 compared to HCC1954-par cells (p = 0.002), and
lapatinib treatment significantly increased p-eEF2 levels
in HCC1954-par cells, with no effect on the levels of
p-eEF2 in HCC1954-L cells (Figure 5B). HCC1954-L
cells had 1.3-fold higher PP2A activity compared to
HCC1954-par cells (p = 0.04) (Figure 5C). OA treatment
of HCC1954-L cells increased p-eEF2 and p-AKT levels
(Figure 5D). HCC1954-L cells exhibited significantly
greater growth inhibition in response to OA treatment
Figure 4 The role of PP2A in eEF2 phosphorylation. (A) Activity of PP2A in SKBR3-par and SKBR3-L cells, untreated and treated with 5 nM OA
for 24 hr. (B) Immunoblot examining the effect of OA alone and in combination with lapatinib on levels of total and phosphorylated eEF2(Thr56)
and AKT(Ser473). (C) Effect of 5 nM okadaic acid (OA) on growth of SKBR3-par and SKBR3-L cells. (D) Effect of OA alone and in combination with
lapatinib on the growth of SKBR3-par cells and (E) SKBR3-L cells. Error bars represent the mean ± SD (n = 3). *denotes p≤ 0.05, **denotes p≤ 0.01.
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(78.0 ± 1.1%) compared to HCC1954-par cells (53.9 ±
3.9%) (p = 0.005) (Figure 5E). Combined treatment with
lapatinib and OA was significantly more effective than
either agent alone, in both HCC1954-par (Figure 5F)
and HCC1954-L cells (Figure 5G).
Discussion
Treatment of HER2-positve breast cancer patients is hin-
dered by resistance to HER2-targeted therapies. In the
present study, we have described the development and
characterization of cell line models of acquired lapatinib
resistance and identified a novel potential target for the
treatment of HER2-positive breast cancer that does not
respond to anti-HER2 therapies.
The SKBR3-L cell line model of acquired lapatinib resist-
ance was developed by continuous long-term (6 month)
exposure to low dose (250 nM) lapatinib, in contrast to
previous studies which utilized high-dose lapatinib and/or
dose escalation procedures [18-24]. The median peak
plasma concentration of lapatinib reported in patients re-
ceiving 1200 mg lapatinib (once daily) was 1.2 μg/ml (2.1
μM) and the median steady-state trough concentration
Figure 5 PP2A regulates eEF2 phosphorylation in an additional cell line model of acquired lapatinib resistance. (A) Effect of lapatinib on
growth of HCC1954-par and HCC1954-L cells. (B) Immunoblot analysis of total and phosphorylated eEF2(Thr56) in HCC1954-par and HCC1954-L
cells following 24 hr lapatinib treatment. (C) Activity of PP2A in HCC1954-par and HCC1954-L cells, untreated and treated with 5 nM OA for 24 hr.
(D) Immunoblot examining the effect of okadaic acid (OA) alone and in combination with lapatinib on levels of total and phosphorylated eEF2(Thr56)
and AKT(Ser473). (E) Effect of 5 nM OA on growth of SKBR3-par and SKBR3-L cells. (F) Effect of OA alone and in combination with lapatinib on the
growth of HCC1954-par cells and (G) HCC1954-L cells. *denotes p≤ 0.05, **denotes p≤ 0.01. Error bars represent the mean ± SD (n = 3).
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was 0.3 μg/ml (0.5 μM), with a range of 0.2-0.5 μg/ml [25].
To our knowledge, the models of acquired lapatinib resist-
ance presented here, SKBR3-L and HCC1954-L, are the
first to show that extended exposure to concentrations of
lapatinib in the steady state trough concentration range,
results in significant lapatinib resistance, with resulting
lapatinib IC50 values significantly higher than the concen-
tration used for conditioning. Interestingly, SKBR3-L cells
do not exhibit any significant alterations in XIAP, SRC or
ER expression, as have been described in other models of
lapatinib resistance [20,21,23]. Furthermore, Jegg et al [24]
recently developed another SKBR3 model of acquired
lapatinib resistance using escalating doses of lapatinib,
which resulted in constitutive activation of mTOR; we did
not observe this alteration in the SKBR3-L cells. There-
fore, the resistance mechanisms triggered by lapatinib ex-
posure may be concentration dependent.
SKBR3-L cells exhibit cross-resistance to both trastu-
zumab (anti-HER2) and gefitinib (anti-EGFR). Cross-
resistance to trastuzumab has previously been reported
in a cell line model of acquired lapatinib resistance [26],
but to our knowledge cross-resistance to gefitinib has
not previously been reported. Interestingly, acquired
trastuzumab resistance may not be accompanied by
cross-resistance to anti-HER2 tyrosine kinase therapy, as
trastuzumab conditioned breast cancer cell lines retained
lapatinib sensitivity [15]. Phosphorylation of both HER2
and EGFR in SKBR3-L cells is inhibited by lapatinib treat-
ment, which is consistent with other cell line models of
acquired lapatinib resistance [21,22,26], suggesting that
the mechanisms of resistance to lapatinib, trastuzumab
and gefitinib lie downstream of HER2/EGFR.
PI3K mutation and/or loss of PTEN have been shown
to contribute to maintained activation of AKT and are
associated with innate resistance to trastuzumab [8] and
lapatinib [27]. In our study, SKBR3-L cells exhibit a dra-
matic decrease in p-AKT compared to parental cells,
suggesting a decreased dependence on the P13K path-
way for growth and survival, and no alteration in PTEN
levels was observed. A decrease in p-MAPK was also ob-
served indicating that numerous alterations in protein
phosphorylation/kinase signaling pathways are occurring
simultaneously in SKBR3-L cells. Thus, we compared the
global phosphorylation pattern of SKBR3-L and SKBR3-par
cells using 2D-gel electrophoresis coupled with MALDI-
Tof/Tof mass spectrometry analysis, a technique which has
been successfully applied to the study of altered protein
phosphorylation [28]. eEF2 showed the largest decrease in
phosphorylation levels in SKBR3-L compared to the SKBR3
parental cells and was selected for further analysis.
eEF2 plays a critical role in regulating protein synthesis.
Phosphorylation of eEF2thr56 prevents it from binding to
the ribosome, which results in the termination of protein
translation [29]. eEF2 is phosphorylated by eEF2k [30], the
activity of which is negatively regulated by phosphoryl-
ation at Ser366 via mTOR signaling [31] and by phosphor-
ylation at Ser359 by MAPK13 or CDK1 [32], preventing
its phosphorylation of eEF2. SKBR3-par cells responded
to lapatinib treatment with increased p-eEF2thr56; however,
no increase in p-eEF2 was observed in SKBR3-L cells, sug-
gesting inhibition of protein synthesis in SKBR3-par cells
only. Consistent with this we found higher levels of
phosphorylated eEF2k at both Ser366 and Ser359, and in-
creased expression of eEF2k, suggesting that decreased
eEF2k activity may contribute to decreased eEF2 phos-
phorylation in SKBR3-L cells. NH125 is an eEF2k inhibi-
tor which decreases the phosphorylation of eEF2 [33].
NH125 treatment decreased eEF2k activity in SKBR3-par
cells and significantly decreased eEF2 phosphorylation.
However, the effect of eEF2k inhibition on lapatinib sensi-
tivity was limited, suggesting that decreased eEF2k activity
is not a major mediator of acquired lapatinib resistance.
We also examined if inhibition of mTOR signaling by
rapamycin alters the phosphorylation of eEF2 in SKBR3-L
cells. We found that SKBR3-L cells have lower p-mTOR
levels, are less sensitive to rapamycin and do not exhibit
increased eEF2 phosphorylation in response to rapamycin,
suggesting that constitutive activation of mTOR is not a
major regulator of eEF2 phosphorylation in this lapatinib-
resistant model. Although eEF2k is the only known kinase
to phosphorylate eEF2thr56, a recent study reports a
novel mode of eEF2 regulation, whereby phosphoryl-
ation of eEF2 at Ser595 by CDK2 stimulates phosphoryl-
ation at Thr56 by eEF2k [34]; further investigation is
required to determine if Ser595 phosphorylation is altered
in SKBR3-L cells, however our studies with NH125 sug-
gest that eEF2k activity does not play a significant role in
acquired lapatinib resistance in SKBR3-L cells.
Phosphorylation of eEF2 is also negatively regulated by
PP2A, a family of protein phosphatases that functions to
dephosphorylate multiple proteins [35]. Transgenic mice
overexpressing PP2A exhibit increased eEF2 dephos-
phorylation [36], and inhibitors of PP2A attenuate eEF2
dephosphorylation [37]. While PP2A was initially reported
to be a tumor suppressor [38], recent studies have found
that only some individual subunits of PP2A have tumor
suppressor functions that are context dependent; PP2A
activity has been associated with leukemic cell survival
[39], pancreatic cancer cell growth [40], and has been cor-
related with poor survival in glioblastoma [41]. While
altered PP2A activity has not previously been reported
as a mechanism of lapatinib resistance, there is evidence
that inhibition of HER2 signaling can result in increased
PP2A activity in a lapatinib sensitive breast cancer cell
line [42]. However, the same study also reported a cor-
relation between decreased PP2A activity and tumor
progression for HER2 positive breast tumors, which is
more consistent with the role of PP2A as a tumor
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suppressor. We examined the activity of PP2A in SKBR3-L
and HCC1954-L cells and found significantly higher activ-
ity of PP2A and increased sensitivity to the PP2A inhibitor
OA, both alone and in combination with lapatinib, com-
pared to parental cells. The combined treatment with OA
and lapatinib resulted in an increase in the percentage of
cells in sub-G1, in a cell cycle assay, which suggests an in-
crease in apoptosis induction. Furthermore, inhibition of
PP2A restored the phosphorylation of eEF2 in both resist-
ant cell lines. These results suggest that increased PP2A
activity contributes to the acquired resistant phenotype.
Pre-treatment of SKBR3 parental cells with the PP2A
activator FTY720 [43] decreased sensitivity to lapatinib,
suggesting a causative role for PP2A activation in the de-
velopment of acquired lapatinib resistance in this model.
PP2A inhibition did not appear to improve response to
trastuzumab in the SKBR3-L cells, suggesting that there
may be other alterations in the cells that contribute to tras-
tuzumab resistance. Further work is required to elucidate
the mechanism leading to increased PP2A activity in ac-
quired anti-HER2 therapy resistance and the role of PP2A
as a potential mediator of acquired resistance. Assessment
of PP2A levels and/or activity in tumor samples following
exposure to lapatinib will be required to determine the
clinical significance of this potential resistance mechanism.
Fostriecin, a potent and selective inhibitor of PP2A,
was tested as a cancer therapy in a phase I clinical trial
but the trial was suspended due to drug instability [44].
Cantharidin, an inhibitor of PP1, PP2A, PP4 and PP5,
has been used as an anticancer agent in traditional medi-
cine but has been largely ignored by Western medicine
due to toxicities. However, less toxic and more selective
derivatives of cantharidin have been developed and have
been shown to enhance response to chemotherapy in
preclinical models of glioma, sarcoma and metastatic
pheochromocytoma [45-48]. A phase I trial of LB-1, alone
and in combination with docetaxel, in advanced solid
tumors is currently ongoing (NCT01837667).
Conclusions
In summary, we report increased PP2A activity and acti-
vated eEF2 in two cell lines models of acquired lapatinib
resistance. We demonstrate that PP2A inhibition signifi-
cantly enhances the growth inhibitory effects of lapatinib
in both sensitive and resistant cell lines. These data pro-
vide novel potential biomarkers of lapatinib resistance
and support the rationale for further investigation of
combined PP2A and HER2 inhibition as a therapeutic
strategy for refractory HER2 positive breast cancer.
Methods
Cells lines and reagents
SKBR3 and HCC1954 cells were obtained from ATCC
and maintained in RPMI 1640 (Sigma-Aldrich) with
10% fetal calf serum (GE Healthcare). Stock solutions
(10 mM) of lapatinib (provided by GlaxoSmithKline), gefi-
tinib (Sequoia Research Products), Okadaic acid (Santa-
CruzBiotechnology), NH125 (Calbiochem) and FTY720
(Sigma-Aldrich) were prepared in dimethyl sulfoxide.
Trastuzumab was obtained from St. Vincent’s University
Hospital, Dublin Ireland.
Proliferation assay
Proliferation was measured using an acid phosphatase
assay; 1.5-3 × 103 cells were seeded in 96-well plates, in-
cubated overnight prior to addition of drug. After 5 days
cells were washed with PBS. 10 mM paranitrophenol
phosphate substrate (Sigma-Aldrich) in 0.1 M sodium
acetate buffer with 0.1% Triton X (Sigma Aldrich) was
added to each well and incubated at 37°C for 2 hours.
50 μl of 1 M NaOH was added and the absorbance was
read at 405 nM (reference—620 nM). Growth of drug
treated cells was calculated relative to control untreated
cells in biological triplicate.
Establishment of lapatinib-resistant cell lines
The IC70 concentration of 4 day lapatinib treatment on
SKBR3 cells was determined using the acid phosphatase
method. SKBR3 cells were treated with 250 nM lapatinib
twice weekly for 6 months, the IC50 of lapatinib in the
parental and conditioned cells was measured to deter-
mine resistance, and the resulting cell line was denoted
as SKBR3-L. Parental cells (SKBR3-par cells) were cul-
tured alongside the conditioned cells. HCC1954-L and
HCC1954-par cells were also established using the above
technique using 1 μM lapatinib; the IC70 concentration
for HCC1954 cells treated with lapatinib for 4 days.
Resistant cells were maintained continuously in the pre-
sence of lapatinib, however, prior to all assays lapatinib
was removed from the cells for 1 week.
Cell cycle assay
2.5 × 104 cells were seeded per well in a 24 well plate
and incubated at 37°C. After 24 hours, 3 nM okadaic
acid, 100 nM or 500 nM lapatinib, or a combination of 3
nM okadaic acid with 100 nM or 500 nM lapatinib were
added to each well. Following 48 hours incubation, media
was collected and the wells were rinsed with PBS. Cells
were trypsinized and added to collected media. The media
was centrifuged at 300 × g for 5 minutes and the super-
natant was aspirated. 150 μl of PBS was added to the
pellet, re-suspended and transferred to a round bottom
96-well plate. The plate was centrifuged at 300 × g for 5
minutes and the supernatant was removed, leaving ap-
proximately 15 μl per well. The remaining volume was re-
suspended and 200 μl of ice cold 70% ethanol was added.
The plate was stored for 2 hours at -20°C. After fixing the
cells, the plate was spun at 450 × g for 5 minute. The
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supernatant was removed, 200 μl of PBS was added and
the plate was centrifuged again at 450 × g for 5 minutes.
The PBS was removed and 200 μl of Guava Cell Cycle re-
agent was added to each well. The cells were resuspended
and stored at room temperature in the dark for 30 mi-
nutes. Cells were then analyzed on the Guava EasyCyte
(Guava Technologies) and the data was analyzed using
Modfit LT software (Verify Software House).
2D-gel electrophoresis and MALDI-TOF mass spectrometry
SKBR3-par and SKBR3-L cells were cultured to 90%
confluent in biological triplicate, total protein was ex-
tracted and phosphoprotein fragments were concen-
trated using the Pierce™ Phosphoprotein Enrichment Kit
(Pierce Biotechnology) according to the kit instructions
using the lysis buffer provided supplemented with
CHAPS (0.25%), 1X Halt Protease Inhibitor EDTA-free
and 1X Halt Phosphatase Inhibitor Cocktail (Pierce Bio-
technology). Cy-labelled samples were run on 2D-DIGE
gels as previously described [28]. To account for any la-
beling bias by the different dyes, reciprocal labeling
experiments were carried out. Any proteins showing dif-
ferential effects specific to the use of the Cy3/Cy5 dyes
were removed from the analysis. A mixed (equal pool of
all samples) internal standard labeled with Cy2 was in-
cluded. This internal standard, which contains every
protein present across all samples in the experiment,
was applied to all the replicate gels together with dis-
tinct Cy3- and Cy5-labelled samples, thereby ensuring
inter- and intra-gel matching. The unique signal of every
protein in the internal standard was used for quantitative
comparisons within each gel and for normalization of the
spots across the various gels. Gels were scanned with the
Typhoon 9400 Variable Mode Imager (GE Healthcare).
The biological variation analysis (BVA) module of Decyder
6.5 was used to generate lists of differentially expressed
proteins. Preparative gels stained with colloidal CBB stain
(Sigma-Aldrich) were scanned using the Typhoon and
images were then matched to the Master gel image gen-
erated from the DIGE experiment. Spots of interest
were selected and tryptic digestions were performed
with the Ettan Digestor robot (GE Healthcare), using
2.5 ng/ml trypsin in 40 mM NH4HCO3 in 10% aceto-
nitrile solution overnight at 37°C. Digested peptides
were eluted in 70% acetonitrile, lyophilized and resus-
pended in 0.1% TFA solution in 50% acetonitrile. The
peptide extract added to a 384 spot MALDI sample plate
(Applied Biosystems) and supplemented with 0.5 μl of a 5
mg/ml solution of recrystalized α-cyano-4-hydroxy-trans-
cinnamic acid matrix plus 10 mM NH4H2PO4 in 50%
acetonitrile/water containing 0.1% TFA. MALDI mass
spectra were generated using a 4800 TOF/TOF Proteo-
mics Analyzer instrument (Applied Biosystems), using a
Pep4 internal calibrant. The MS and MS/MS data were
combined and searched against a number of databases
using GPS Explorer software (Applied Biosystems) and a
local MASCOT (Matrix Science, London, UK) search en-
gine for protein identification. Pathways associated with
the phospho-proteins identified were determined using
Panther software ((http://www.pantherdb.org/) [49,50].
Immunoblot analysis
30 μg of protein were separated on polyacrylamide gels
(Lonza), transferred to nitrocellulose membranes (Invitro-
gen) and blocked for 1 hour in blocking solution (2.5%
milk powder (Biorad) in PBS containing 0.1% Tween-20
(PBS-T)). Membranes were incubated at 4°C overnight
with primary antibody at a 1:1000 dilution in blocking so-
lution (unless otherwise stated) against p-HER2tyr1221/1222,
p-EGFRtyr1173, AKT, p-AKTser473, ERK, pERKthr202/tyr204,
eEF2, p-eEF2thr56, mTOR, p-mTORser2448, eEF2k, p-
eEF2kser366 (Cell Signaling Technology), p-eEF2kser359
(1:200) (SantaCruzBiotechnology), HER2 (Calbiochem),
EGFR (1:250) (Neomarkers), and α-tubulin, anti-mouse
and anti-rabbit secondary antibodies (Sigma-Aldrich).
Detection was performed using Luminol (SantaCruzBio-
technology) or ECL Advance (GE Healthcare).
PP2A activity assay
PP2A activity was measured using a serine/threonine
phosphatase assay kit (Promega). Briefly, cells were lysed
(50 mM Tris-HCl pH 7.5, 0.05% Triton X-100, 0.1 mM
EDTA, 0.5 mM PMSF, 0.05% β-mercaptoethanol, 10%
glycerol) with protease inhibitors (Sigma-Aldrich) for 40
mins with frequent vortexing. Free phosphate was re-
moved by filtering through Sephadex G25 column and
protein concentration was determined using the Bradford
assay (Biorad). 2.5 μg of sample was loaded to a 96-well
plate with peptide substrate RRA(pT)VA in PP2A-specific
reaction buffer (250 mM imidazole pH 7.2, 1 mM EGTA,
0.1% β-mercaptoethanol, 0.5 mg/ml BSA), at 37°C for 20
min. After incubation 50 μl of molybdate dye/additive
mixture was added and allowed to develop for 20 mins,
the plate was read at 630 nM.
Statistical analysis
Each experiment was performed with a minimum of three
biological replicates for each condition. IC50 concentra-
tions were determined using CalcuSyn software (Biosoft).
Densitometry was performed using ImageQuant software
(GE Healthcare) whereby phosphoprotein was normalized
to total protein and the results were normalized to α-
tubulin as a loading control. Analysis of the difference of
comparisons in protein levels and response to treatment
was performed using the Student t-test (two-tailed with
unequal variance).
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Additional files
Additional file 1: Figure S1. Analysis of previously published lapatinib
resistance mechanisms. Immunoblot analysis of XIAP, estrogen receptor α
(ER), total and phosphorylated SRC and PTEN in SKBR3-par and SKBR3-L
cells following 24 hr. lapatinib treatment.
Additional file 2: Table S1. Phosphoproteins in SKBR3-L compared to
SKBR3-par cells. List of identified phosphoproteins with ≥ 1.2-fold increase
or decrease in levels in SKBR3-L compared to SKBR3 cells.
Additional file 3: Figure S2. Concentration dependent effect on
NH125 on lapatinib sensitivity. SKBR3-par cells were pre-treated with
either 100 nM (A, B and C) or 250 nM (D, E and F) NH125 for 24 hours,
after which time NH125 was removed from the cells and they were
treated with either 100 nM lapatinib (A and D), 250 nM lapatinib (B and
E) or 500 nM lapatinib (C and F) and the percentage growth of the cells
was compared cells treated with lapatinib only. Growth is expressed
relative to control untreated cells. Error bars represent the standard
deviation of triplicate experiments.
Additional file 4: Figure S3. (A) Proliferation assay in SKBR3-L cells
treated with okadaic acid (3 nM) alone and in combination with
trastuzumab and (B) cell cycle assay in SKRB3-L treated with okadaic acid
(3 nM) with/without lapatinib. Error bars represent the standard deviation
of triplicate experiments.
Additional file 5: Figure S4. SKBR3 parental cells were pretreated with
2.5 μM FTY720 for 24 hours prior to a 5 day treatment with a range of
lapatinib concentrations of lapatinib (0-612.5 nM). Cell growth was
measured after 5 days of lapatinib treatment. Growth is expressed relative
to control untreated cells. Error bars represent the standard deviation of
triplicate experiments.
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